What's so special about transtuzumab?

Drug and Therapeutics Bulletin

Volumn 40, Issue 9, 2002, Pages 65-67

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIRUBICIN; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ANGIONEUROTIC EDEMA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; BREAST CANCER; BRONCHOSPASM; CANCER HORMONE THERAPY; CARDIOTOXICITY; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DYSPNEA; FEMALE; FEVER; HEADACHE; HUMAN; HYPOTENSION; LICENSING; MAJOR CLINICAL STUDY; METASTASIS; MUSCLE WEAKNESS; MYALGIA; NAUSEA AND VOMITING; RASH; THORAX PAIN; TREATMENT CONTRAINDICATION; TREATMENT FAILURE; WHEEZING; BREAST TUMOR; METABOLISM; MULTIMODALITY CANCER THERAPY; REVIEW;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; RECEPTOR, ERBB-2;

EID: 0036740720     PISSN: 00126543     EISSN: None     Source Type: Journal    
DOI: 10.1136/dtb.2002.40965     Document Type: Article

References (11)

1. Slamon DJ et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-12.
2. Guidance on the use of trastuzumab for the treatment of advanced breast cancer
3. Perez EA. Current management of metastatic breast cancer. Semin Oncol 1999; 26 (suppl 12): 1-10.
4. Carter P et al. Humanization of an anti-p185 HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 1992; 89: 4285-9.
5. Slamon DJ et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses. HER2. N Engl J Med 2001; 344: 783-92.
6. Osoba D et al. Effects on quality-of-life of combined trastuzumab and chemotherapy in women with metastatic breast cancer. J Clin Oncol 2002; 20: 3106-13.
7. Vogel CL et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 719-26.
8. Cobleigh MA et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17: 2639-48.
9. Herceptin. Summary of product characteristics
10. Crone S et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat. Med 2002; 8: 459-65.
11. Seidman A et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002; 20: 1215-21.